Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine) [PDF]
, 2021 The critical concentrations for culture-based phenotypic drug susceptibility testing (DST) to first-line anti-TB drugs have been revised by the the World Health Organization (WHO).
Fournier Le Ray, Laure +14 more
core
Emerging Dissemination of blaCTX‐M‐65 in Bovine E. coli in Spain Associated With IncHI2 Plasmids
MicrobiologyOpen, Volume 15, Issue 3, June 2026.The resistome in ESBL/AmpC‐producing E. coli in livestock was diverse and dominated by plasmid‐borne genes Detection of host‐independent dissemination of AMR determinants mediated by shared plasmid types First report in Spanish cattle of blaCTX‐M‐65 on IncHI2 plasmids, an under‐reported ESBL in Europe Identification of potentially zoonotic clones in ...
Medelin Ocejo +2 more
wiley +1 more source
Guidelines: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis in HIV-Infected Patients Taking Protease Inhibitors or Non-nucleoside Reverse Transcriptase Inhibitors [PDF]
, 2005 Two previously published reports provided guidelines for managing the pharmacological interactions that can result when patients are treated with protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) for human ...
Centers for Disease Control and Prevention,
core +1 more source
Efficacy of rifapentine and other rifamycins against Coxiella burnetii in vitro
Microbiology SpectrumSince 1999, doxycycline and hydroxychloroquine have been the recommended treatment for chronic Q fever, a life-threatening disease caused by the bacterial pathogen, Coxiella burnetii. Despite the duration of its use, the treatment is not ideal due to the
Halie K. Miller, Gilbert J. Kersh
doaj +1 more source
MicrobiologyOpen, Volume 15, Issue 3, June 2026.Clostridioides difficile infections are increasingly problematic in areas with already burdened healthcare systems. From a One‐Health perspective, a lack of surveillance in developing countries greatly contributes to the limited information available on the zoonotic and foodborne potential of C. difficile.
M. Gouws, P. E. Strydom, D. Rip
wiley +1 more source
mBioThe emergence of multidrug-resistant Gram-negative bacteria underscores the need to define genetic vulnerabilities that can be therapeutically exploited.
Ryan D. Ward +5 more
doaj +1 more source
Cefdinir reprograms Gram‐positive bacteria to synergize with lysozyme against superbugs
mLife, Volume 5, Issue 3, Page 355-368, June 2026.Abstract Multidrug‐resistant (MDR) bacteria pose a critical global health threat, urgently requiring solutions. Cefdinir, the highest‐selling third‐generation cephalosporin but one now facing clinical obsolescence due to escalating resistance, is conventionally classified as a nascent cell wall synthesis inhibitor.
Qi Zhang +6 more
wiley +1 more source
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections [PDF]
, 2016 The clinical management of prosthetic joint infections and other persistent bacterial infections represents a major unmet medical need. The rifamycins are one of the most potent antibiotic classes against persistent bacterial infections, but bacteria can
Anthony Simon Lynch (2864234) +1 more
core +1 more source
Diene Substitution Patterns in the Conformation‐Activity Relationships of GEX1A
ChemMedChem, Volume 21, Issue 10, 27 May 2026.Synthetic analogues of GEX1A were designed and synthesised in an effort to explore the significance of diene substitution on the conformational preferences and expand our understanding of the three‐dimensional pharmacophore for this biologically active natural product.
Christian A. Umaña +5 more
wiley +1 more source
Internship Reports and Monograph "Rifamycins in the Inhibition of RNAP" [PDF]
Relatório de Estágio do Mestrado Integrado em Ciências Farmacêuticas apresentado à Faculdade de FarmáciaWe are currently living in a global public health crisis that is affecting various therapies.
Araújo, Vânia Pombo
core